Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 12
Summary
- Conditions
- Glioma
- Recurrent Malignant Glioma
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02658279
- Collaborators
- Merck Sharp & Dohme Corp.
- M.D. Anderson Cancer Center
- Dana-Farber Cancer Institute
- University of California, San Francisco
- Huntsman Cancer Institute/ University of Utah
- University of California, Los Angeles
- University of Miami
- Investigators
- Principal Investigator: Thomas Kaley, MD Memorial Sloan Kettering Cancer Center
Get Well Soon